Integer Holdings (ITGR)
(Delayed Data from NYSE)
$131.49 USD
-0.94 (-0.71%)
Updated Oct 15, 2024 04:00 PM ET
After-Market: $131.54 +0.05 (0.04%) 7:58 PM ET
4-Sell of 5 4
C Value B Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$131.49 USD
-0.94 (-0.71%)
Updated Oct 15, 2024 04:00 PM ET
After-Market: $131.54 +0.05 (0.04%) 7:58 PM ET
4-Sell of 5 4
C Value B Growth C Momentum B VGM
Zacks News
Here's Why Investors Should Retain CONMED (CNMD) Stock Now
by Zacks Equity Research
CONMED's (CNMD) steady focus on innovation is indicative of brighter prospects ahead. The company faces cutthroat competition in the niche space.
Becton, Dickinson's MAX Enteric Viral Panel Cleared by FDA
by Zacks Equity Research
Becton, Dickinson's (BDX) Diagnostic Systems portfolio lends it a competitive edge.
Here's Why You Should Buy Intuitive Surgical (ISRG) Now
by Zacks Equity Research
A solid outlook for 2018 and strength in robotics make Intuitive Surgical (ISRG) a promising investment pick.
Medtronic's Growth Across All Lines Aid, Rising Costs Ail
by Zacks Equity Research
Of late, Medtronic (MDT) succeeds in delivering solid top-line growth at CER, backed by balanced growth across major business operation.
Myriad Genetics Posts Positive Adjusted Vectra Test Data
by Zacks Equity Research
The key finding of Myriad Genetics' (MYGN) study proves that the adjusted Vectra score beats all traditional measures of disease activity to predict radiographic progression in RA patients.
SYK vs. SRDX: Which MedTech Stock Should Investors Pick?
by Zacks Equity Research
Surmodics (SRDX) scores higher than Stryker (SYK) in terms of current-year revenue projections and fundamentals.
Varian Medical's (VAR) Halcyon Excluded From Trade Tariffs
by Zacks Equity Research
Recent trade war-related talks are likely to favor Varian Medical (VAR) in the long run.
Here's Why You Should Hold Becton, Dickinson (BDX) Stock Now
by Zacks Equity Research
Plethora of developments for Becton, Dickinson (BDX); headwinds apprehended in fiscal 2019.
Here's Why You Should Buy Integer Holdings (ITGR) Stock Now
by Zacks Equity Research
As a result of continued efforts to streamline operations, Integer Holdings (ITGR) has been registering strong profits over the last couple of quarters.
Here's Why You Should Invest in Genomic Health (GHDX) Now
by Zacks Equity Research
Having established a strong foothold in the U.S. market, Genomic Health (GHDX) is now expanding considerably in the international arena.
Integra Rides on Global Prospects, Hurt by Escalating Costs
by Zacks Equity Research
Integra LifeSciences (IART) aims at investment openings in the Asian market for a faster business boost than in the United States and also to flourish specific parts of its international businesses.
Quest Diagnostics (DGX) Divests India Business to Strand
by Zacks Equity Research
Quest Diagnostics (DGX) sees lucrative prospects in the U.S. diagnostic testing market.
Hill-Rom Grows on Acquisitions, Asia Pacific Sales Drop
by Zacks Equity Research
Hill-Rom (HRC) is actively pursuing buyouts to accelerate growth across five key clinical areas.
Cala Health Picks Medidata Cloud for Observational Study
by Zacks Equity Research
Medidata's (MDSO) Cloud platform sees a slew of developments in recent times.
Here's Why You Should Invest in Stryker (SYK) Stock Right Now
by Zacks Equity Research
Stryker (SYK) continues to gain from its Mako robotics platform, which has been the key driver of the company's core Orthopaedic segment.
Walgreens (WBA) Q1 Earnings Top Estimates, Margins Down
by Zacks Equity Research
Walgreens' (WBA) retail Pharmacy USA division witnessed comparable prescription growth and benefited from a strong retail prescription market.
Inogen Gains From Commercial Launch of Wireless Connect
by Zacks Equity Research
Inogen's (INGN) expanding product portfolio lends it a competitive edge in the respiratory care devices market.
Myriad Genetics' New FDA Nod for BRACAnalysis CDx Widens Base
by Zacks Equity Research
Myriad Genetics (MYGN) progresses well with initiatives to boost the uptake of the BRACAnalysis CDx test. The recent approval to increase the customer base is an added positive.
Here's Why You Should Invest in STERIS (STE) Stock Right Now
by Zacks Equity Research
With the acquisition of U.K.-based outsourced sterilization services provider Synergy Health, STERIS (STE) has become the global leader in infection prevention and sterilization.
Here's Why You Should Hold HealthEquity (HQY) Stock for Now
by Zacks Equity Research
HealthEquity's (HQY) fiscal third-quarter results hold promise while competition is stiff.
Medtronic's Mazor Buyout Creates a New Spine Surgery Major
by Zacks Equity Research
With the acquisition of Mazor Robotics, Medtronic (MDT) expects to offer a fully-integrated procedural solution for surgical planning, execution and confirmation.
Baxter Stock up on Launch of Disposable Curved Applicator
by Zacks Equity Research
Baxter's (BAX) wide array of surgical products see lucrative market prospects.
New Strong Buy Stocks for December 19th
by Nitish Marwah
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:
GNC Holdings Global Business Strong, Same Store Sales Weak
by Zacks Equity Research
GNC Holdings' (GNC) domestic franchise revenues worsen due to soft retail same store sales and fewer franchise stores.
Here's Why You Should Hold Cooper Companies (COO) Stock Now
by Zacks Equity Research
Cooper Companies' (COO) strong CVI segment favors the stock while a soft Fertility unit raises concern.